{"id":354163,"date":"2025-08-18T12:25:14","date_gmt":"2025-08-18T12:25:14","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/354163\/"},"modified":"2025-08-18T12:25:14","modified_gmt":"2025-08-18T12:25:14","slug":"catheter-precisions-locket-suture-device-wins-uk-market-approval","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/354163\/","title":{"rendered":"Catheter Precision&#8217;s LockeT Suture Device Wins UK Market Approval"},"content":{"rendered":"<p>&#13;<br \/>\n    &#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<\/p>\n<p><b>Catheter Precision (NYSE:VTAK)<\/b> has received regulatory approval for its <b>LockeT suture retention device<\/b> in the United Kingdom, following its CE Mark approval in May 2025. The company has partnered with <b>HC21<\/b>, a major UK-based distributor with \u20ac180 million in annual revenue and 500+ employees across the UK and Ireland.<\/p>\n<p>The LockeT device is designed to enhance patient comfort, enable earlier discharge after cardiac procedures, and support NHS efforts to reduce waiting lists. The company will distribute the product through HC21&#8217;s established network, leveraging their existing partnership to bring the innovative cardiac device to the UK healthcare market.<\/p>\n<p><b>Catheter Precision (NYSE:VTAK)<\/b> ha ottenuto l&#8217;autorizzazione normativa per il suo <b>LockeT suture retention device<\/b> nel Regno Unito, dopo il CE Mark ricevuto nel maggio 2025. L&#8217;azienda ha siglato una partnership con <b>HC21<\/b>, principale distributore con sede nel Regno Unito, che registra ricavi annui di 180 milioni di euro e oltre 500 dipendenti nel Regno Unito e in Irlanda.<\/p>\n<p>Il dispositivo LockeT \u00e8 progettato per migliorare il comfort del paziente, consentire dimissioni anticipate dopo procedure cardiache e sostenere gli sforzi del NHS per ridurre le liste d&#8217;attesa. Il prodotto sar\u00e0 distribuito attraverso la rete consolidata di HC21, sfruttando la loro presenza esistente per introdurre questo dispositivo cardiaco innovativo nel mercato sanitario del Regno Unito.<\/p>\n<p><b>Catheter Precision (NYSE:VTAK)<\/b> ha obtenido la aprobaci\u00f3n regulatoria para su <b>LockeT suture retention device<\/b> en el Reino Unido, tras recibir el marcado CE en mayo de 2025. La compa\u00f1\u00eda se ha asociado con <b>HC21<\/b>, un importante distribuidor con sede en el Reino Unido que factura 180 millones de euros anuales y cuenta con m\u00e1s de 500 empleados en Reino Unido e Irlanda.<\/p>\n<p>El dispositivo LockeT est\u00e1 dise\u00f1ado para aumentar la comodidad del paciente, permitir altas m\u00e1s tempranas tras procedimientos card\u00edacos y apoyar los esfuerzos del NHS para reducir las listas de espera. La empresa distribuir\u00e1 el producto a trav\u00e9s de la red establecida de HC21, aprovechando su colaboraci\u00f3n para introducir este innovador dispositivo cardiaco en el sistema sanitario del Reino Unido.<\/p>\n<p><b>Catheter Precision (NYSE:VTAK)<\/b>\ub294 2025\ub144 5\uc6d4 CE \ub9c8\ud06c \uc2b9\uc778\uc5d0 \uc774\uc5b4 \uc601\uad6d\uc5d0\uc11c \uc790\uc0ac\uc758 <b>LockeT suture retention device<\/b>\uc5d0 \ub300\ud55c \uaddc\uc81c \uc2b9\uc778 \uc744 \ud68d\ub4dd\ud588\uc2b5\ub2c8\ub2e4. \ud68c\uc0ac\ub294 \uc5f0\uac04 \ub9e4\ucd9c 1\uc5b5 8\ucc9c\ub9cc \uc720\ub85c, \uc601\uad6d\uacfc \uc544\uc77c\ub79c\ub4dc\uc5d0 500\uba85 \uc774\uc0c1\uc758 \uc9c1\uc6d0\uc774 \uc788\ub294 \uc601\uad6d \uae30\ubc18 \uc8fc\uc694 \uc720\ud1b5\uc0ac <b>HC21<\/b>\uc640 \ud30c\ud2b8\ub108\uc2ed\uc744 \ub9fa\uc5c8\uc2b5\ub2c8\ub2e4.<\/p>\n<p>LockeT \uc7a5\uce58\ub294 \ud658\uc790 \ud3b8\uc548\ud568\uc744 \uac1c\uc120\ud558\uace0 \uc2ec\uc7a5 \uc2dc\uc220 \ud6c4 \uc870\uae30 \ud1f4\uc6d0\uc744 \uac00\ub2a5\ud558\uac8c \ud558\uba70, NHS\uc758 \ub300\uae30\uc790 \uba85\ub2e8 \uac10\uc18c \ub178\ub825\ub3c4 \uc9c0\uc6d0\ud558\ub3c4\ub85d \uc124\uacc4\ub418\uc5c8\uc2b5\ub2c8\ub2e4. \uc774 \uc81c\ud488\uc740 HC21\uc758 \ud655\ub9bd\ub41c \uc720\ud1b5\ub9dd\uc744 \ud1b5\ud574 \uacf5\uae09\ub418\uc5b4 \uc601\uad6d \uc758\ub8cc \uc2dc\uc7a5\uc5d0 \uc774 \ud601\uc2e0\uc801\uc778 \uc2ec\uc7a5 \uc7a5\uce58\ub97c \ub3c4\uc785\ud560 \uc608\uc815\uc785\ub2c8\ub2e4.<\/p>\n<p><b>Catheter Precision (NYSE:VTAK)<\/b> a re\u00e7u l&#8217;approbation r\u00e9glementaire pour son <b>LockeT suture retention device<\/b> au Royaume-Uni, apr\u00e8s l&#8217;obtention du marquage CE en mai 2025. La soci\u00e9t\u00e9 s&#8217;est associ\u00e9e \u00e0 <b>HC21<\/b>, un important distributeur bas\u00e9 au Royaume-Uni r\u00e9alisant 180 millions d&#8217;euros de chiffre d&#8217;affaires annuel et employant plus de 500 personnes au Royaume-Uni et en Irlande.<\/p>\n<p>Le dispositif LockeT vise \u00e0 am\u00e9liorer le confort du patient, permettre des sorties plus pr\u00e9coces apr\u00e8s des interventions cardiaques et soutenir les efforts du NHS pour r\u00e9duire les listes d&#8217;attente. Le produit sera distribu\u00e9 via le r\u00e9seau \u00e9tabli de HC21, tirant parti de leur pr\u00e9sence existante pour introduire ce dispositif cardiaque innovant sur le march\u00e9 de la sant\u00e9 britannique.<\/p>\n<p><b>Catheter Precision (NYSE:VTAK)<\/b> hat f\u00fcr sein <b>LockeT suture retention device<\/b> in Gro\u00dfbritannien die beh\u00f6rdliche Zulassung erhalten, nach der CE-Kennzeichnung im Mai 2025. Das Unternehmen ist eine Partnerschaft mit <b>HC21<\/b> eingegangen, einem gro\u00dfen britischen Vertriebspartner mit einem Jahresumsatz von 180 Mio. \u20ac und \u00fcber 500 Mitarbeitern in Gro\u00dfbritannien und Irland.<\/p>\n<p>Das LockeT-Ger\u00e4t wurde entwickelt, um den Patientenkomfort zu erh\u00f6hen, fr\u00fchere Entlassungen nach Herzverfahren zu erm\u00f6glichen und die Bem\u00fchungen des NHS zur Reduzierung von Wartelisten zu unterst\u00fctzen. Das Produkt wird \u00fcber das etablierte Netzwerk von HC21 vertrieben, wodurch deren bestehende Partnerschaft genutzt wird, um dieses innovative Herzger\u00e4t in den britischen Gesundheitsmarkt zu bringen.<\/p>\n<p>Positive<\/p>\n<ul>&#13;<br \/>\n            &#13;<\/p>\n<li>Received UK regulatory approval for LockeT device, expanding market reach<\/li>\n<p>&#13;<br \/>\n            &#13;<\/p>\n<li>Partnership with established distributor HC21 (\u20ac180M revenue, 500+ employees)<\/li>\n<p>&#13;<br \/>\n            &#13;<\/p>\n<li>Product aligns with NHS goals to reduce waiting lists and improve efficiency<\/li>\n<p>&#13;<br \/>\n            &#13;<\/p>\n<li>Already secured CE Mark approval in May 2025 for European distribution<\/li>\n<p>&#13;<br \/>\n            &#13;\n          <\/ul>\n<p>      &#13;<\/p>\n<p>&#13;<br \/>\n          Insights  &#13;\n        <\/p>\n<p>&#13;<br \/>\n    &#13;<\/p>\n<p class=\"tldr\"><b>Catheter Precision expands market reach with UK approval for LockeT device, strengthening European commercial footprint.<\/b><\/p>\n<p>Catheter Precision&#8217;s newly secured UK approval for its LockeT suture retention device represents a <b>significant market expansion<\/b> following its CE Mark certification in May 2025. The UK registration completes the regulatory requirements needed for commercialization in this key European market.<\/p>\n<p>The distribution partnership with HC21 is particularly strategic given HC21&#8217;s established presence with <b>\u20ac180 million in annual revenue<\/b> and over 500 employees across the UK and Ireland. This leverages an existing relationship as Catheter Precision has previously worked with HC21 for other product lines, suggesting operational synergies and established channels.<\/p>\n<p>The LockeT device addresses a specific clinical need in cardiac electrophysiology procedures, with potential to improve patient outcomes while simultaneously offering healthcare system benefits. The company&#8217;s positioning of the product as supporting <b>NHS efficiency goals<\/b> by enabling earlier patient discharge aligns with the UK healthcare system&#8217;s priorities to reduce waiting lists \u2013 a metric where the NHS has recently achieved its first reduction in 17 years.<\/p>\n<p>For Catheter Precision, this approval represents expanded commercial opportunities in the competitive cardiac electrophysiology market. The UK healthcare system, with approximately 100,000 cardiac device procedures annually, represents a substantial market opportunity for specialized devices that can improve procedural efficiency and patient throughput in cardiac care units.<\/p>\n<p>          &#13;<br \/>\n        &#13;<\/p>\n<p>&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n    &#13;<br \/>\n    &#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n      08\/18\/2025 &#8211; 08:00 AM&#13;<br \/>\n      &#13;<br \/>\n    &#13;<br \/>\n&#13;<\/p>\n<p align=\"justify\"><strong>FORT MILLS, S.C., Aug.  18, 2025  (GLOBE NEWSWIRE) &#8212; <\/strong>Catheter Precision, Inc. (<a href=\"https:\/\/www.stocktitan.net\/overview\/VTAK\" title=\"View VTAK stock overview\" class=\"symbol-link\" target=\"_blank\" rel=\"noopener\">VTAK<\/a> &#8211; NYSE\/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced registration and approval in the United Kingdom for its LockeT product, a suture retention device. LockeT received CE Mark for European approval and distribution in May 2025. Obtaining registration was the final approval required to launch sales in the UK.<\/p>\n<p align=\"justify\">Catheter Precision has partnered with <a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=cEgg1XvzxExBWmpVwwB2c9qYbTUpdsDlyW0EqLuAGqgUuf2ERDFy0Z8nVzar25yN_ddWvFr7bZayakqwRc05NQ==\" target=\"_blank\">HC21<\/a>, a UK-based value-added distributor for several years with a different product line and has entered into an additional agreement to distribute LockeT. With an\u00a0annual revenue of \u20ac180 million\u00a0and more than\u00a0500+ employees\u00a0across the UK and Ireland, HC21 works with many of the world\u2019s leading medical device companies to drive growth and achieve quicker, more efficient routes to market though existing and new channels.<\/p>\n<p align=\"justify\">Fatih Ayoglu, Sales Manager EMEA &amp; APAC, said &#8220;We are proud to announce the approval of LockeT for use in the United Kingdom, marking a significant milestone in our mission to support healthcare systems with innovative, patient-centric solutions. LockeT\u2019s intuitive design and ease of deployment not only enhance patient comfort and recovery but also enable earlier discharge following cardiac procedures. This directly supports NHS efforts to reduce waiting lists by freeing up hospital capacity and accelerating patient throughput. With the NHS recently achieving its first reduction in waiting lists in 17 years, LockeT is poised to contribute meaningfully to this momentum by helping clinicians deliver more treatments, more efficiently. We look forward to working closely with UK healthcare providers to bring LockeT\u2019s benefits to patients nationwide.&#8221;<\/p>\n<p align=\"justify\"><strong>About LockeT<\/strong><br \/>Catheter Precision\u2019s <a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=kEGKobxkabi2KbRcQ2V8WbqAt7MAIPHk-Mty8sxm4g5NsYNx5t9BIyTXgAgqeqhqbPLG4FetPCXRKciU9VA2GcP9StXriv6fr7fhnfzQQ4hnPriqx_uA_rAH7YLMGGeE\" target=\"_blank\">LockeT<\/a> is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.<\/p>\n<p align=\"justify\"><strong>About Catheter Precision<\/strong><br \/><a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=-E2Aws4b1u_O25llDcxTewULGSSThPyvIG7KBQoY3bhcURdikg8d_Et3T_6s4PQU9v4fKH1Tx7AjD9XB8NAs4-p-yB82buxEX1EiUMBimcY=\" target=\"_blank\">Catheter Precision<\/a> is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.<\/p>\n<p align=\"justify\"><strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><br \/>Statements in this press release may contain \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as \u201cbelieve,\u201d \u201canticipate,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201ccan,\u201d \u201ccould,\u201d \u201ccontinue,\u201d \u201cdepends,\u201d \u201cexpect,\u201d \u201cexpand,\u201d \u201cforecast,\u201d \u201cintend,\u201d \u201cpredict,\u201d \u201cplan,\u201d \u201crely,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cseek,\u201d or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. \u00a0These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company\u2019s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption \u201cRisk Factors\u201d in the Company\u2019s Form 10-K filed with the SEC and available at www.sec.gov.<\/p>\n<p align=\"justify\">The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.<\/p>\n<p align=\"justify\"><strong>CONTACTS:<\/strong><\/p>\n<p align=\"justify\"><strong>Investor Relations<\/strong><br \/>973-691-2000<br \/><a rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=fzhTwFaKCcDb3DHaJy6l1OgmSfgHPcZqDvsO9dxcUyb_DLcJXDPfG6UACRWvB9qrHneJ2azcpFuRR_3wGqeoJTXYmvEx0LQDccVt187rnVgYVG4slf5NtspACo6bkfK_\" target=\"_blank\">IR@catheterprecision.com<\/a><\/p>\n<p align=\"justify\"># # #<\/p>\n<p> <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/08\/ti\"\/> <br \/><img decoding=\"async\" alt=\"\" src=\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2025\/08\/Catheter-Precision-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"\/>&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n      &#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n  &#13;<br \/>\n&#13;<\/p>\n<p>&#13;<br \/>\n    FAQ  &#13;\n  <\/p>\n<p>&#13;<br \/>\n  &#13;<br \/>\n  &#13;<\/p>\n<p>        When did Catheter Precision (VTAK) receive UK approval for LockeT?<\/p>\n<p>&#13;<br \/>\n          Catheter Precision received UK approval for its LockeT suture retention device in <b>August 2025<\/b>.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        What is the LockeT device by Catheter Precision (VTAK)?<\/p>\n<p>&#13;<br \/>\n          LockeT is a <b>suture retention device<\/b> designed for the cardiac electrophysiology market that enhances patient comfort and enables earlier discharge following cardiac procedures.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        Who will distribute LockeT in the UK market?<\/p>\n<p>&#13;<br \/>\n          <b>HC21<\/b>, a UK-based distributor with \u20ac180 million in annual revenue and 500+ employees across the UK and Ireland, will distribute LockeT.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        When did Catheter Precision&#8217;s LockeT receive CE Mark approval?<\/p>\n<p>&#13;<br \/>\n          LockeT received its <b>CE Mark approval in May 2025<\/b> for European distribution.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<\/p>\n<p>        How will LockeT benefit the UK healthcare system?<\/p>\n<p>&#13;<br \/>\n          LockeT will support <b>NHS efforts to reduce waiting lists<\/b> by enabling earlier patient discharge, freeing up hospital capacity, and accelerating patient throughput following cardiac procedures.&#13;\n        <\/p>\n<p>    &#13;<br \/>\n  &#13;<br \/>\n&#13;<br \/>\n&#13;<br \/>\n    &#13;<br \/>\n&#13;<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; &#13; &#13; &#13; &#13; &#13; &#13; &#13; Catheter Precision (NYSE:VTAK) has received regulatory approval for its LockeT&hellip;\n","protected":false},"author":2,"featured_media":354164,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,4],"tags":[14636,748,125008,125013,125003,125011,12920,393,125012,4884,125010,125005,125006,125014,211,1144,712,125009,16,125007,15,125004,1764],"class_list":{"0":"post-354163","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-uk","8":"category-united-kingdom","9":"tag-apac","10":"tag-britain","11":"tag-cardiac-electrophysiology","12":"tag-cardiac-procedures","13":"tag-catheter-precision","14":"tag-ce-mark","15":"tag-emea","16":"tag-england","17":"tag-european-approval","18":"tag-great-britain","19":"tag-hc21","20":"tag-locket","21":"tag-medical-device-approval","22":"tag-medical-distribution","23":"tag-nhs","24":"tag-northern-ireland","25":"tag-scotland","26":"tag-suture-retention-device","27":"tag-uk","28":"tag-uk-healthcare","29":"tag-united-kingdom","30":"tag-vtak","31":"tag-wales"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115049760456412009","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/354163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=354163"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/354163\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/354164"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=354163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=354163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=354163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}